Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy
Authors:
- Frank SiebenhaarFSFrank Siebenhaar
- Wolfgang KühnWKWolfgang Kühn
- Torsten ZuberbierTZTorsten Zuberbier
- Marcus MaurerMMMarcus Maurer
- 1 July 2007
- journal article
- other
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 120 (1) , 213-215
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosisJournal of Allergy and Clinical Immunology, 2007
- Anti-IgE as a mast cell–stabilizing therapeutic agentJournal of Allergy and Clinical Immunology, 2006
- Mastocytosis: Pathology, genetics, and current options for therapyLeukemia & Lymphoma, 2005
- Regulation of mast-cell and basophil function and survival by IgENature Reviews Immunology, 2002
- Omalizumab, a novel anti-IgE therapy in allergic disordersExpert Opinion on Biological Therapy, 2001
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Immunologic aspects of Meniere's diseaseAmerican Journal of Otolaryngology, 1999
- Fortnightly review: Diagnosis and treatment of Meniere's diseaseBMJ, 1998
- Committee on Hearing and Equilibrium Guidelines for the Diagnosis and Evaluation of Therapy in Meniere's Disease∗Otolaryngology–Head and Neck Surgery, 1995